Serological evidence of Anaplasma spp., Borrelia burgdorferi and Ehrlichia canis in dogs from the Republic of Korea by rapid diagnostic test kits
Background: Emergent and re-emergent canine tick-borne infections are attracting increasing attention worldwide. The rise in pet ownership and the close relationship between dogs and their owners are the most concerning factors because dogs may act as competent reservoirs for human tick-transmitted infectious agents.
Objectives: This study contributes to the epidemiological surveillance of canine tick-transmitted infections with zoonotic risk in the Republic of Korea (ROK) by investigating the seroprevalence of the pathogens, Anaplasma spp., Borrelia burgdorferi, and Ehrlichia canis.
Methods: Four hundred and thirty whole blood samples from domestic dogs were collected in seven metropolitan cities and nine provinces in the ROK and tested using SensPERT Ab test kits (VetAll Laboratories®) to detect seroreactive animals.
Results: The seroprevalence rates identified were 9.8% (42/430) for Anaplasma spp., 2.8% (12/430) for B. burgdorferi, and 1.4% (6/430) for E. canis. The risk factors evaluated in this study that could be associated with the development of a humoral immune response, such as sex, age, and history of tick exposure, were similar. There was only one exception for dogs seroreactive to Anaplasma spp., where the risk factor “tick exposure” was statistically significant (p = 0.047).
Conclusions: This serological survey exhibited the widespread presence of Anaplasma spp., B. burgdorferi, and E. canis throughout the ROK. Hence, dogs may play a key role as the sentinel animals of multiple zoonotic infectious agents in the country.
Performance Evaluation of In Vitro Screening and Diagnostic Kits for Hepatitis C Virus Infection
Aim: A reliable kit with high sensitivity and specificity is indispensable for diagnosing hepatitis C virus (HCV) infection. Detection kits for anti-HCV antibodies (anti-HCV) are used for screening, and quantification kits for HCV RNA and HCV antigen (Ag) are used for the definite diagnosis of HCV infection or the evaluation of the pathological condition of and therapeutic effects in patients with chronic hepatitis C. Several kits are currently available for these purposes and are provided for clinical use in Japan. In this study, we aimed to evaluate the performance of these kits.
Methods: We used International Standards for HCV RNA and HCV Ag and a regional reference panel to evaluate the performance of thirteen anti-HCV, five HCV RNA, and two HCV Ag kits.
Results: All specimens in the regional reference panel were diagnosed correctly by all anti-HCV kits, although the distributions of the quantified values varied, and the ratios of titer classification were not identical across kits. All HCV RNA kits quantified the International Standard with minimum deviation and diagnosed the specimens of the reference panel correctly. The quantified values of the International Standard by two HCV Ag kits were inconsistent. HCV Ag titers of some specimens were underestimated owing to the amino acid polymorphisms in comparison with HCV RNA titers.
Conclusions: The evaluation with International Standards and the regional reference panel was useful for assessing the quality of screening and diagnostic kits for HCV infection, and such quality control is essential for the clinical usage of these kits.
The anti-KIT monoclonal antibody CDX-0159 induces profound and durable mast cell suppression in a healthy volunteer study
Background: Mast cells (MC) are powerful inflammatory immune sentinel cells that drive numerous allergic, inflammatory and pruritic disorders when activated. MC-targeted therapies are approved in several disorders, yet many patients have limited benefit suggesting the need for approaches that more broadly inhibit MC activity. MCs require the KIT receptor and its ligand stem cell factor (SCF) for differentiation, maturation, and survival. Here we describe CDX-0159, an anti-KIT monoclonal antibody that potently suppresses MCs in human healthy volunteers.
Methods: CDX-0159-mediated KIT inhibition was tested in vitro using KIT-expressing immortalized cells and primary human mast cells. CDX-0159 safety and pharmacokinetics were evaluated in a 13-week good laboratory practice (GLP)-compliant cynomolgus macaque study. A single ascending dose (0.3, 1, 3 and 9 mg/kg), double-blinded placebo-controlled phase 1a human healthy volunteer study (n=32) was conducted to evaluate the safety, pharmacokinetics and pharmacodynamics of CDX-0159.
Results: CDX-0159 inhibits SCF-dependent KIT activation in vitro. Fc modifications in CDX-0159 led to elimination of effector function and reduced serum clearance. In cynomolgus macaques, multiple high doses were safely administered without a significant impact on hematology, a potential concern for KIT inhibitors. A single dose of CDX-0159 in healthy human subjects was generally well tolerated and demonstrated long antibody exposure. Importantly, CDX-0159 led to dose-dependent, profound suppression of plasma tryptase, a MC-specific protease associated with tissue MC burden, indicative of systemic MC suppression or ablation.
Conclusion: CDX-0159 administration leads to systemic mast cell ablation and may represent a safe and novel approach to treat mast cell-driven disorders.
EdU Imaging Kits (488) |
|||
| K1175-50 | ApexBio | 50-500 tests | 240 EUR |
BSA Standard kits |
|||
| TBS5002 | Tribioscience | 7x 1ml | 45 EUR |
Tricorn Filter Kits |
|||
| TFK-013C | Creative BioMart | each | 320 EUR |
T&A Cloning Kits |
|||
| FYC001-20P | Yeastern Biotech | 1 vial | Ask for price |
EdU Imaging Kits (Cy3) |
|||
| K1075-50 | ApexBio | 50-500 tests | 240 EUR |
EdU Imaging Kits (Cy5) |
|||
| K1076-50 | ApexBio | 50-500 tests | 240 EUR |
EdU Imaging Kits (HF488) |
|||
| K2240-50 | ApexBio | 50-500tests | 240 EUR |
EdU Imaging Kits (HF594) |
|||
| K2243-50 | ApexBio | 50-500tests | 240 EUR |
Necrosis vs Apoptosis Kits |
|||
| KF17371 | Neuromics | 50-100 Tests | 522 EUR |
Necrosis vs Apoptosis Kits |
|||
| KF17372 | Neuromics | 100-200 Tests | 921.6 EUR |
Basic Cytotoxicity Test Kits |
|||
| CT17001 | Neuromics | 125 Tests | 490.8 EUR |
Basic Cytotoxicity Test Kits |
|||
| CT17002 | Neuromics | 250 Tests | 780 EUR |
Total Cytotoxicity Test Kits |
|||
| CT17003 | Neuromics | 125 Tests | 615.6 EUR |
Total Cytotoxicity Test Kits |
|||
| CT17004 | Neuromics | 250 Tests | 975.6 EUR |
Gel Filtration Calibration Kits |
|||
| Ge-474C | Creative BioMart | 1 Kit | 1704 EUR |
Uncoated Ancillary Reagent Kits |
|||
| RK04587 | Abclonal | 20Plates | 280 EUR |
EdU Flow Cytometry Assay Kits (488) |
|||
| K1176-100 | ApexBio | 100 tests | 340 EUR |
MitoPT™ TMRE & TMRM Kits |
|||
| KF17358 | Neuromics | 500 Test | 574.8 EUR |
MitoPT™ TMRE & TMRM Kits |
|||
| KF17359 | Neuromics | 500 Test | 574.8 EUR |
Total bile acid (TBA) kits |
|||
| SH0118 | Jiaxing Korain Biotech Ltd (BT Labs) | 96T | 240 EUR |
Rat Neural Stem Cell Kits |
|||
| PC37123 | Neuromics | 1 X 10(6) *minimum order 6 vials* | 1148.4 EUR |
HiPer® Teaching Kits-Handbook |
|||
| MBTL001-1NO | EWC Diagnostics | 1 unit | 11.97 EUR |
Carcass Sponge Sampling Kits - PK95 |
|||
| SWA1038 | Scientific Laboratory Supplies | PK95 | 434.7 EUR |
Sealed Vials Calibration Kits - EACH |
|||
| 2659505 | Scientific Laboratory Supplies | EACH | 1013.85 EUR |
HISTAR DETECTION SYSTEM Kits (OKSA11259) |
|||
| OKSA11259 | Aviva Systems Biology | 50 Tests | 678 EUR |
HISTAR DETECTION SYSTEM Kits (OKSA11260) |
|||
| OKSA11260 | Aviva Systems Biology | 150 Tests | 1602 EUR |
Effects of increasing levels of orange peel extract on kit growth, feed utilization, and some blood metabolites in the doe rabbits under heat stress conditions
One of the most severe consequences of climate change on the rabbit production sector is heat stress. Dietary supplementation of phytochemicals could alleviate the negative impact of heat stress on rabbits. Thirty-six V-line rabbit does with average live body weight (LBW) of 2.672 ± 0.031 kg were randomly allocated into three experimental groups as follows: the control group (OPE0) and the OPE2.5 and OPE5 groups were orally administered orange peel extract (OPE) at doses of 2.5 and 5 mL/doe. The increasing OPE levels significantly improved LBW at partum (p = 0.002) and weaning (p = 0.004), daily and total feed intake from pregnancy until weaning (p = 0.007), daily milk yield per doe at 7th and 14th days (p ≤ 0.05), and milk efficiency (p = 0.001).
Litter size at 1st-28th days, litter weight gain, survival rate, and kit weight gain at 21st-28th days of heat-stressed doe rabbits were significantly improved with OPE treatments. The treatment of OPE5 significantly decreased serum glucose, triglycerides, and very-low-density lipoprotein-cholesterol levels of rabbits. The increasing OPE levels decreased significantly total lipid and low-density lipoprotein-cholesterol levels and increased (p = 0.001) high-density lipoprotein-cholesterol concentration in heat-stressed rabbits. In conclusion, the treatment of OPE improved feed utilization, milk efficiency, and reproductive performance and alleviated the drastic impacts of heat stress on rabbits.